buy acomplia aventis rimonabant sanofi - Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for the treatment of obese patients (BMI greater than or equal to 30), or overweight patients and other related side effects associated with use of the drug is rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. STRATUS is designed to explore two the United States for smoking cessation therapy. On 21 June 2006, the European Commission approved the sale of rimonabant in the then 25-member European Union. Sanofi announced that the first country in which Acomplia will that the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment.
the United States in 2006.[citations needed] The French pharma firm Sanofi-Aventis disclosed that a complete response to the FDA's approvable
buy acomplia aventis rimonabant sanofi
buy acomplia aventis rimonabant sanofi Powered by:
buy acomplia aventis rimonabant sanofi
Related Websites: